Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Phase 2Active, not recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 7
01
Overview
A Phase 2 trial of brogidirsen in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc.. Started Feb 2024; status: active, not recruiting.
02
Drugs
brogidirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05996003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996003.